Company Overview and News
Associate Finance Minister David Parker today announced the next phase of overseas investment rule reviews, following the house sale ban which takes effect from next week.
AIA FBU FBU AIA FCREY ACKDF FRCEF AUKNY
I'm not at Gold Elite level but I've certainly spent more time in the air than I ever would have imagined as a young girl growing up in small-town New Zealand.
AIA AIA ANZLY AIR ANZFF ANZFY ACKDF AUKNY AIZ
New Zealand shares ended a nine-day losing streak, with A2 Milk Co and blue-chip stocks such as Spark New Zealand, Mercury NZ and Auckland International Airport driving the recovery.
AIA AIR SPKKY NZTCY SPK NZTCF ACKDF ANZFY AUKNY AIZ KWIPF AIA ANZLY ANZFF MEZ PFGTF
New Zealand shares fell for a seventh day. Rising US bond yields kept a lid on equity markets across Asia, weighing on growth-orientated stocks such as A2 Milk Co and Pushpay Holdings.
AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ SKT ZNZ SYKWF PPSHY SKKTY SML AIA FBU RHCGF SPKKY NZTCY SPK ZEL FRCEF AIA FBU ANZLY RYHTY ANZFF MEZ
New Zealand shares fell for a sixth session as rising US bond yields dented investors' appetite for stocks. Synlait Milk led the market lower, dropping to a five-month low.
C6L PYIYY AIR NZTCF SINGY ACKDF ANZFY AUKNY AIZ GNE PPSHY GEL SML AIA SPKKY NZTCY SPK AIA ANZLY ANZFF GNE GTK MEZ PFI SINGF
The government has extended a partnership between Air New Zealand and Singapore Airlines for another five years, saying it creates stronger bonds with South East Asia.
AIA C6L AIA ANZLY AIR ANZFF SINGY ANZFY ACKDF AUKNY AIZ SINGF
New Zealand shares fell for a fourth day as A2 Milk Co remains out of favour after recent selling by its chief executive and a director. Genesis Energy and Auckland International Airport also declined after shedding rights to dividend payments.
CEN AIA FBU RHCGF FCREY CMO RYM ACKDF FRCEF AUKNY COENY KWIPF COENF GNE AIA PPSHY FBU RYHTY CEN GNE MEZ GEL
New Zealand shares slipped as the weakest business confidence in nine years and fears over future profitability weighed on stocks linked to the local economic cycle.
AIA FBU RHCGF AIR FCREY SPKKY NZTCY SPK NZTCF RYM ACKDF FRCEF ANZFY AUKNY AIZ SKT SYKWF AIA PPSHY FBU ANZLY RYHTY SKKTY ANZFF
New Zealand shares fell as A2 Milk Co extended its decline since its chief executive sold down her holding. Rising bond yields also dimmed the lustre of property stocks.
AIA FBU FCREY SPKKY EBOSY NZTCY SPK NZTCF ACKDF FRCEF EBO AUKNY KWIPF AOTUF EBOSF SKC AIA FBU THL VTHPF SKLUY SKL MEZ EBO
New Zealand shares edged higher as improved confidence lifted building and tourism stocks. Rising oil prices kept investors nervous about higher energy costs for companies, and was identified as a headwind for Air New Zealand at its annual meeting.
CEN PYIYY AIR FCREY ZNRGF ACKDF ANZFY AUKNY AIZ COENF ZNZ CEN SML AIA FBU ZEL FRCEF COENY KWIPF AIA FBU THL ANZLY ANZFF MEZ PFI
New Zealand shares edged higher as investors wait for the upcoming round of annual meetings for a clearer steer on company outlooks.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ COENF SKT SYKWF CEN SKKTY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY OHE ANZFF MEZ
Auckland International Airport has announced development of a new $30-40 million hotel, converting and expanding existing commercial premises into the new offering.
AIA AIA ACKDF AUKNY
New Zealand shares joined the global rally in equity markets as the prospect of improving trade relations between the US and China lifted investor confidence. Pushpay Holdings led the market higher after getting a broker upgrade.
AIA FBU AIR FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF ANZFY AUKNY AIZ FTRRF AIA PPSHY FBU THL ANZLY ANZFF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:AIA / AUCKLAND INTERNATIONAL AIRPORT LIMITED on message board site Silicon Investor.
|Gaiam||Gaiam||Gaiam||Altavista mines (AIA.m)||Altavista mines (AIA.m)||Altavista mines (AIA.m)|